Latest News Archive

Please select Category, Year, and then Month to display items

Fighting COVID-19: Here is how we are helping

16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish

Farmovs — In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19.

The trial is expected to include more than 45 countries worldwide, including a number of South African sites.

Farmovs
FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients.

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe. FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.

News Archive

Final lecture in Darwin series presented at the UFS

2010-02-23

At the lecture were, from the left: Prof. Terence McCarthy, Prof. Jo van As, Chairperson of the Darwin 200 Committee and Head of the Department of Zoology and Entomology at the UFS, Prof. Bruce Rubidge, Elsabe Brits, journalist at Die Burger and Esther van der Westhuizen, presenter on Groen.
Photo: Leonie Bolleurs

The University of the Free State (UFS), in collaboration with the Central University of Technology, Free State (CUT) and The National Museum in Bloemfontein recently hosted the final lecture on the Charles Darwin lecture series entitled “The story of life and survival”.

The lecture was presented by Prof. Bruce Rubidge, the Director of the Bernard Price Institute for Paleontological Research at Wits University and Prof. Terence McCarthy, a Professor of Mineral Geochemistry at Wits and Head of the Department of Geology. Proff. Rubidge and McCarthy are co-authors of the book The Story of Life on Earth.

Their lecture with the topic “Trends in evolution and their bearing on the future of humankind” dealt with the future of evolution. According to Prof. Rubidge, ninety-nine percent of the species that have ever lived are extinct. “We are living in a time of mass extinction. Fifty thousand species become extinct annually,” he said.

Prof. McCarthy discussed many factors that can result in mankind’s extinction today. The impact of climate change, big volcanic eruptions, a comet or asteroid hitting earth, tsunamis and the collapsing of sea islands are some of the factors Prof. McCarthy believes could cause great catastrophe’s on earth.

“We live on the brink of this all the time,” he said.

Prof. McCarthy also believes that we can avoid these catastrophes. By allowing only one child per family we can shrink the global population with 30% per generation. This is doable in a short time span,” he said.

Other ideas he had on saving mankind from getting extinct is to create extensive ecological reserves on land but especially in the ocean, to decentralise everything, to change to renewable energy, to recycle resources and to be vigilant in doing this.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept